International immunopharmacologyAnimalsHumansImmunotherapyAdoptiveLeukemia
CAR T cells targeting B7H3 demonstrate potent preclinical activity against AML and ESCC.
Chang Liu, Jinping Zhao, Xuhua Zhang, Cheng Gao, Zhihao Wang, Huiting Wu, Mengjia Zhang, Tingting Wang, Lu Han, Yanan Jiang, Jing Lu, Tao Wang, Jing An, Xianlei Sun, Yurong Chai
Published: 202610.1016/j.intimp.2025.115806
Abstract
T cells engineered to express chimeric antigen receptors (CARs) are a promising modality to treat refractory cancers. CD19 CAR-T therapy has achieved remarkable responses in against B-cell lymphomas, however, challenges persist for acute myeloid leuk…
Preview only. Read the full abstract at the source